Richard Price
Price, Ric
VIAF ID: 305038890 (Personal)
Permalink: http://viaf.org/viaf/305038890
Preferred Forms
-
- 100 1 _ ‡a Price, Ric
- 100 0 _ ‡a Richard Price
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
The epidemiology of Plasmodium vivax, 2012- : | |
Mefloquine in infants and young children. | |
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. | |
Molecular Epidemiology of P. vivax in Iran: High Diversity and Complex Sub-Structure Using Neutral Markers, but No Evidence of Y976F Mutation at pvmdr1. | |
Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malaria | |
Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. | |
Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia | |
Multi-locus genotyping reveals established endemicity of a geographically distinct Plasmodium vivax population in Mauritania, West Africa | |
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia | |
Neurosyphilis: Still prevalent and overlooked in an at risk population | |
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance | |
A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes | |
Nocardiosis in the Tropical Northern Territory of Australia, 1997-2014. | |
Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum | |
An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples | |
Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria | |
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria | |
Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection | |
The pathophysiology of vivax malaria | |
Performance and user acceptance of the Bhutan febrile and malaria information system: report from a pilot study | |
The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. | |
Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. | |
Plasmodium falciparum activates CD16+ dendritic cells to produce TNF and IL-10 in subpatent malaria | |
Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes | |
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine | |
Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance | |
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity | |
The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes. | |
Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution | |
Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study | |
Plasmodium vivax: clinical spectrum, risk factors and pathogenesis | |
Plasmodium vivax infection: a major determinant of severe anaemia in infancy | |
Plasmodium vivax: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. | |
Plasmodium vivax treatments: what are we looking for? | |
Platelets kill circulating parasites of all major Plasmodium species in human malaria | |
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine | |
Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. | |
Potential of artemisinin-based combination therapies to block malaria transmission | |
Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection | |
Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. | |
Prolongation of the QTc interval in African children treated for falciparum malaria | |
Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis | |
Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry | |
Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. | |
Quinolone-3-diarylethers: a new class of antimalarial drug. | |
Rapid clinical assessment to facilitate the triage of adults with falciparum malaria, a retrospective analysis | |
The relationship between age and the manifestations of and mortality associated with severe malaria | |
The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria | |
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria | |
Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report | |
The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study | |
The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network | |
The role of standby emergency medication for falciparum malaria: current opinion | |
Safety profile of L-arginine infusion in moderately severe falciparum malaria | |
Severe congenital malaria acquired in utero | |
Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia | |
A simple score to predict the outcome of severe malaria in adults | |
Single-dose radical cure of Plasmodium vivax: a step closer | |
Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation | |
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. | |
A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults | |
Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia | |
A systematic review of published antimalarial clinical trials: parasite clearance of artemisinin-containing regimens in the treatment of uncomplicated malaria | |
A systematic review of sub-microscopic Plasmodium vivax infection | |
Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency | |
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance | |
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia | |
Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes | |
Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia | |
Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades | |
A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria | |
Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection | |
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria | |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study | |
Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis. | |
Variation in Complexity of Infection and Transmission Stability between Neighbouring Populations of Plasmodium vivax in Southern Ethiopia | |
Vivax malaria: a major cause of morbidity in early infancy | |
The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials |